Brainstorm Cell Therapeutics (BCLI) to Release Quarterly Earnings on Wednesday

Brainstorm Cell Therapeutics (NASDAQ:BCLI) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.07). On average, analysts expect Brainstorm Cell Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Brainstorm Cell Therapeutics Price Performance

Shares of NASDAQ:BCLI opened at $0.60 on Tuesday. The firm has a market capitalization of $6.62 million, a PE ratio of -0.18 and a beta of 0.12. The firm’s 50-day moving average is $1.01 and its two-hundred day moving average is $1.25. Brainstorm Cell Therapeutics has a 1 year low of $0.52 and a 1 year high of $6.00.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Maxim Group lowered shares of Brainstorm Cell Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 23rd. Wall Street Zen upgraded shares of Brainstorm Cell Therapeutics to a “sell” rating in a research note on Saturday, June 14th.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.